Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,024.67 +3,727.03 (+6.29%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Iterum Therapeutics plc (ITRM)
After hours:
| Previous close | 1.5700 |
| Open | 1.5800 |
| Bid | 1.5100 x 100 |
| Ask | 1.6000 x 100 |
| Day's range | 1.5200 - 1.6300 |
| 52-week range | 0.6220 - 2.5000 |
| Volume | |
| Avg. volume | 203,880 |
| Market cap | 25.66M |
| Beta (5Y monthly) | 2.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.50 |
GlobeNewswireIterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has resubmitte
Insider MonkeyIterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript March 28, 2024 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.02. ITRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, everyone, and welcome to the […]
- Thomson Reuters StreetEvents
Q4 2023 Iterum Therapeutics PLC Earnings Call
Q4 2023 Iterum Therapeutics PLC Earnings Call
